JMP maintains J&J at market perform

Johnson & Johnson Inc. was maintained by JMP Securities analyst Robert C. Faulkner at market perform after the company reported earnings in line with expectations. Sales were $13.16 billion compared with JMP's estimate of $13.23 billion Earnings per share of $0.99 was below the analyst's estimate of $1.01. Indications are that the slowdown in the U.S. orthopedic reconstructive implant market continues. Shares of the New Brunswick, N.J., pharmaceutical company were down 11 cents, or 0.19%, at $58.02 on volume of 9,145,600 shares versus the three-month running average of 9,524,870 shares. (NYSE: JNJ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.